Crossmark

Efficacy and safety of colistin–doxycycline combination therapy in multi-drug resistance Gram-negative infections: a double-blind randomized controlled trial

Crossref DOI link: https://doi.org/10.1007/s15010-025-02698-3

Published Online: 2025-11-20

Published Print: 2026-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Abaft, Shaghayegh

Yassin, Zeynab

Ahmadinia, Mahdi

Eshraghi, Azadeh

Niari, Behnaz Gholizadeh

Minaeian, Sara

Farasatinasab, Maryam
License Information

Text and Data Mining valid from 2025-11-20

Version of Record valid from 2025-11-20
More Information

Article History

Received: 10 October 2025

Accepted: 18 November 2025

First Online: 20 November 2025

Declarations

:

: This study adhered to the ethical principles of the Declaration of Helsinki and was approved by the Ethics Committee of Iran University of Medical Sciences (Approval ID: IR.IUMS.FMD.REC.1401.132). The trial was prospectively registered in the Iranian Registry of Clinical Trials (IRCT) under the code IRCT20200325046854N4 on August 24, 2024. Written informed consent was obtained from all participants or their legal guardians.

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below